Clyde Biosciences

Founded in 2013, BioAscent is a leading provider of integrated drug discovery services. Our expert scientists provide medicinal chemistry, in vitro biosciences and compound management services from our base in the former Organon / Merck Sharpe and Dohme (MSD) R&D site in Newhouse, Scotland, and via Compound Cloud we offer access to an IP-free compound library in assay ready format.

Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and data management (>100 biochemical and biophysical assays established for drug discovery projects, >50 hit validation/characterisation projects, and >25 hit-to-lead campaigns since 2013). Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications.

We currently hold and manage over 1 million compounds for our customers in our €20 million facility, storing and managing customer libraries ranging in size from a few thousand to a few hundred thousand compounds in both liquid and solid formats. We constantly receive and aggregate new compounds from our customers and their chemistry CRO partners, and ship in the assay-ready format of choice to their screening laboratories

Via our Compound Cloud service, we provide rapid access to an IP-free library of ~125,000 lead like compounds in screening-ready format. Our expertise in cherry picking, reformatting, shipping and data management have allowed us to deliver over 80,000 screening plates globally to our customers and their partner testing laboratories since 2013.

We are located in modern purpose-built laboratories on a single site, the former Organon / Merck Sharpe and Dohme (MSD) research & development facility, based within the BioCity Scotland campus at Newhouse, Scotland, UK.

TGA BioServices, an Absorption Systems'​ Company, is an FDA inspected contract research laboratory providing the Pharmaceutical, Biotechnology and Research communities a comprehensive range of laboratory services in support of research and clinical studies. We offer the client a complete package of customized testing systems utilized in preclinical through Phase IV studies, all in compliance with cGLP and cGMP requirements.

We specialize in the development and validation of immunoassay systems for the detection of target molecules, antibody responses and quantification in total compliance with QA and cGMP standards.

TGA BioServices also offers in vivo mouse studies for the optimization of vaccine immunization schedules, dosing, adjuvant screening, immunogenicity testing for the release and stability of bulk and finished clinical product, as well as complete antibody development programs. Furthermore, we offer Guinea pig dermal sensitization testing for the identification of contact allergens. All programs are supervised by an in-house Institutional Animal Care and Use Committee (IACUC), while the facility is USDA registered and AAALAC accredited.

Other services provided include FACScan cell labeling studies, tissue culture, endotoxin testing, basic R&D activities, sample storage, specimen collection kits with on-site training, data management, protocol generation (SOP), database/statistical analysis and consultation. TGA BioServices has the credentials your project is searching for.

Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry.
Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing.
Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products.

Within Basel neighbourhood and at the very heart of Europe (the triple border of France, Germany and Switzerland), Firalis is a pioneering biotechnology company, active in discovery, development and qualification of biomarkers (BM).

1) BIOMARKER PRODUCTS
Firalis develops BM-based diagnostic, prognostic and theranostic tools:
● RUO Kits (Research-Use-Only), based on validated innovative biomarkers
● IVD Tools (In Vitro Diagnostic), based on a combination of clinically qualified biomarkers

2) BIOMARKER R&D
● Development of proprietary BMs
- Cardiovascular, Inflammatory, Autoimmune and Neurology
● Drug Safety & Drug Efficacy
● Patient Stratification
● Personalized Medicine

3) BIOMARKER-RELATED CRO SERVICES
BM Discovery for laboratories, biotechs and pharmaceutical industry:
- Proteomics: Soluble biomarker measurements with several immunoassays technologies (ELISA, multiplex and high sensitivity platforms such as Luminex® BioPlex 200™, Meso Scale Discovery®, Singulex Erenna®, Protein Simple Ella™, Olink and Siemens Dimension® EXL™ 200)
- Genomics/Transcriptomics: Targeted sequencing of miRNA and mRNA (HTG EdgeSeq), lncRNA screening via Firalis proprietary platform, Next-Generation Sequencing (NGS) services (RNA-Seq, whole genome and exome sequencing, etc.) and qPCR/microfluidic qPCR (Gene Expression, SNP, CNV, etc.)
- Flow Cytometry: Immunophenotyping of preclinical and clinical samples, monitoring of pharmacodynamics on target cells in response to treatment and biomarker discovery
- Assay development and validation on various platforms, development of critical reagents (antibodies and proteins)
- Biobanking and sample repository services supported by LIMS
- Data analysis using multi-parametric statistics and development of predictive models
- Support of regulatory activities related to biomarker qualification with Health Authorities (FDA/EMA)
- Quality environment (ISO 9001, ISO 13485 (GMP), ISO 17025 (GLP/GCLP))

For more information please visit our website.

Soft Flow was founded in the USA in 1988 and moved to Hungary in 1992. Soft Flow is a leading biotechnology company in the fields of flow cytometry, molecular biology and developing analytical solutions for food/feed safety, with almost 30 years of experience in R&D and cooperation with the market leaders in biotechnology and in food analytics. Soft Flow has grown into an internationally recognized R&D Excellence Center which employs over 60 highly qualified people. The company operates in Pécs, Hungary.
In 2016, Soft Flow was acquired by FOSS Analytical, a Danish company known throughout the world for innovative analytical solutions that help to improve food quality and safety in the global food market.
FOSS employs more than 1600 people working all over the world. The analytical instruments are marketed and sold through a global network of sales subsidiaries in 28 countries and by more than 75 dedicated distributors spread over Europe, North, South and Central America, Africa, Asia, and Australia. FOSS research and development is located in two sites, Hillerød and Pécs.

Activities:
Biotechnology Research and Development
- Monoclonal antibody development
- Polyclonal antibody development
- Recombinant protein development
- Phage display
- Conjugational and Organic chemistry
- Immunoassay development (flow cytometry, ELISA, FLISA, lateral flow)

Bioanalytical Services
- Mycotoxin reference analysis
- Antibiotic reference analysis
- Reference chemical analysis from grain, wine, oil, milk
- HCS microscopy

Reagent Production
- Monoclonal antibodies
- Recombinant proteins
- ELISA kits
- Reagents for multiplex microbead matrix technology

Software and Hardware Development, Engineering
- Designing automated measurement systems, instruments
- Planning and testing the Hardware components
- Creating user interfaces to show results (Angular, HTML, CSS)
- Implementing backend services to analyze and store data (.NET Core, C#)
- Controlling HW components using embedded C++